Ministry of Foreign and European Affairs Showcases Decent Cybersecurity at Innovation Day on Cybersecurity
The Ministry of Foreign and European Affairs of the Slovak Republic hosted its 34th "Innovation Day" focused on cybersecurity, presenting Decent Cybersecurity and its partner FREQUENTIS Solutions & Services to ambassadors accredited in Slovakia.
In his opening remarks, Rastislav Chovanec, State Secretary of the Ministry of Foreign and European Affairs of the Slovak Republic, emphasized the critical importance of cybersecurity in today's challenging global environment:
"In a world facing multiple conflicts and global challenges, the security of the Slovak Republic and our citizens is extremely essential, not only in physical form but also in virtual space. Cooperation between the public and private sectors is absolutely necessary in defending against cyber attacks."
Decent Cybersecurity, a leading European provider of post-quantum security solutions, was highlighted for its expertise in post-quantum cryptography. The company develops proprietary algorithms and provides quantum-resistant cybersecurity solutions primarily focused on critical infrastructure, defense industry, and key sectors such as aviation, space, satellite communications, drones, and unmanned traffic management.
Matej Michalko, Founder, CEO and Chairman of Decent Cybersecurity, commented on the significance of the event: "We are honored to be featured at the Innovation Day alongside our valued partner FREQUENTIS Solutions & Services. As cyber threats evolve in complexity, our post-quantum security solutions provide critical protection for the most sensitive infrastructure. This showcase reflects Slovakia's growing leadership in advanced cybersecurity technologies and our commitment to safeguarding digital assets across Europe and beyond."
With offices in Slovakia, Czech Republic, Poland, United Kingdom, and Ireland, Decent Cybersecurity distinguishes itself through innovative use of artificial intelligence and specialized database technology to enhance data protection, system integrity, and confidentiality for high-security sectors.
The company holds national, EU, and NATO "Secret" level security clearances and maintains ISO 9001 and ISO 27001 certifications, independently audited by TÜV SÜD. Decent Cybersecurity is also a certified provider of cybersecurity audits, certified by the National Security Authority.
The Innovation Day highlighted the synergistic partnership between Decent Cybersecurity and FREQUENTIS Solutions & Services, which enables practical verification of Decent Cybersecurity's solutions and accelerates their market entry. FREQUENTIS Solutions & Services specializes in information and communication systems for organizations with security-critical missions, including civil and military air traffic control, air defense, coast guard, police operations centers, firefighters, emergency medical services, public and maritime transport, and space research.
This showcase underscores Slovakia's growing prominence in the cybersecurity sector and the importance of public-private partnerships in addressing evolving cyber threats.
About Decent Cybersecurity
Decent Cybersecurity delivers advanced European cybersecurity solutions specializing in post-quantum security and critical infrastructure protection. The company is a forerunner in utilizing AI, post-quantum cryptography, and quantum-resistant blockchain for enhanced data protection. As a founding member of the Critical Infrastructure Association of the Slovak Republic and recently joined member of the Council of Slovak Exporters, Decent Cybersecurity implements robust security protocols for critical infrastructure and sensitive data across multiple sectors.
About the Ministry of Foreign and European Affairs of the Slovak Republic
The Ministry of Foreign and European Affairs of the Slovak Republic is responsible for the country's foreign policy and international relations. The Ministry represents Slovak interests abroad, promotes economic cooperation, and supports Slovak businesses in international markets. Through initiatives like the Innovation Day series, the Ministry facilitates connections between Slovak companies and the international diplomatic community, showcasing the country's technological capabilities and fostering new business opportunities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250505507729/en/
Contacts
Decent Cybersecurity s.r.o.
Teplicka 4
921 01 Piestany
Slovak Republic
media@decentcybersecurity.eu
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom